In the 12-month, open-label, active-controlled, long-term safety trial in adults and adolescents 12 years of age and older, 404 patients with perennial allergic rhinitis or vasomotor rhinitis were treated with DYMISTA 1 spray per nostril twice daily and 207 patients were treated with fluticasone propionate nasal spray, 2 sprays per nostril once daily. Overall, adverse reactions were 47% in the DYMISTA treatment group and 44% in the fluticasone propionate nasal spray group. The most frequently reported adverse reactions ( ≥ 2%) with DYMISTA were headache, pyrexia, cough, nasal congestion, rhinitis, dysgeusia, viral infection, upper respiratory tract infection, pharyngitis, pain, diarrhea, and epistaxis. In the DYMISTA treatment group, 7 patients (2%) had mild epistaxis and 1 patient ( < 1%) had moderate epistaxis. In the fluticasone propionate nasal spray treatment group 1 patient ( < 1%) had mild epistaxis. No patients had reports of severe epistaxis. Focused nasal examinations were performed and no nasal ulcerations or septal perforations were observed. Eleven of 404 patients (3%) treated with DYMISTA and 6 of 207 patients (3%) treated with fluticasone propionate nasal spray discontinued from the trial due to adverse events.
Must read! my names are Doris carter! from US Austin Texas for a year now i have been living with this virus called HERPES All thanks to Dr Abaka for changing my HERPES Positive to Negative, i do not have much to say, but with all my life i will for ever be grateful to him and God Almighty for using Dr Abaka to reach me when i thought it is all over, today i am a happy man after the medical doctor have confirmed my status Negative,i have never in my life believed that HERPES could be cure by any herbal medicine. so i want to use this medium to reach other persons who have this disease by testifying the wonderful herbs and power of Dr Abaka that all is not lost yet, try and contact him by any means with his email:drabakaspelltemple@ or contact him on whats app +2349063230051 website: https:// .